Atrial Fibrillation in Chronic Kidney Disease: An Overview

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 Sep 15

PMID 36106212

Authors

Sai Gadde

Revanth Kalluru

Swathi Priya Cherukuri

Rahul Chikatimalla

Thejaswi Dasaradhan

Jancy Koneti

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is a condition that can be caused due to any etiology leading to structural damage to the kidney, which can be measured by a decrease in estimated glomerular filtration rate (eGFR) and the presence of damage biomarkers for more than three months. This article has discussed the causal relationship between atrial fibrillation (AF) and CKD, a few of them being inflammation, renin-angiotensin-aldosterone system (RAAS) activation, anemia, and uremia associated with CKD. This review mentioned the clinical impact of the presence of AF in CKD patients. The presence of AF in CKD patients aggravates the renal dysfunction, which in turn adds to the generation of AF. This article explores the various pharmacological and interventional treatment modalities, including antiarrhythmics, anticoagulants, and cardiac ablation, and their complications, leading to restricted usage in CKD patients.

Citing Articles

Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban.

Pina-Beltran B, Dimitrov D, McKay N, Giot M, Zdrahal Z, Potesil D Sci Rep. 2025; 15(1):6075.

PMID: 39972038 PMC: 11839926. DOI: 10.1038/s41598-025-90405-5.

Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease-a systematic review and meta-analysis.

Calderon Martinez E, Sanchez Cruz C, Diarte Acosta E, Aguirre Cano D, Espinosa A, Othon Martinez D J Nephrol. 2024; 38(1):111-126.

PMID: 39614034 PMC: 11903568. DOI: 10.1007/s40620-024-02130-3.

Impact of chronic kidney disease on left atrial appendage occlusion: A meta-analysis of procedural outcomes and complications.

Lee W, Chang W, Shih J, Wu P, Fang C, Chen H Medicine (Baltimore). 2024; 103(29):e38935.

PMID: 39029071 PMC: 11398750. DOI: 10.1097/MD.0000000000038935.

Should We Still Feel Reluctant About Prescribing Rivaroxaban for Advanced Chronic Kidney Disease?.

Ntaios G, Sagris D, Adamou A JACC Adv. 2024; 3(2):100812.

PMID: 38939407 PMC: 11198157. DOI: 10.1016/j.jacadv.2023.100812.

Clinical outcomes and predictors of long-term mortality, hemorrhagic and thromboembolic events in atrial fibrillation patients at different stages of chronic kidney disease: The CRAFT trial.

Styczkiewicz M, Wawrzenczyk M, Peller M, Krzowski B, Maciejewski C, Lodzinski P Int J Cardiol Heart Vasc. 2023; 49:101306.

PMID: 38076348 PMC: 10700826. DOI: 10.1016/j.ijcha.2023.101306.

References

Selvetella G, Lembo G . Mechanisms of cardiac hypertrophy. Heart Fail Clin. 2007; 1(2):263-73. DOI: 10.1016/j.hfc.2005.03.006. View

Hohnloser S, Crijns H, van Eickels M, Gaudin C, Page R, Torp-Pedersen C . Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360(7):668-78. DOI: 10.1056/NEJMoa0803778. View

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell R . Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77(12):1098-106. DOI: 10.1038/ki.2009.477. View

Martinon F, Burns K, Tschopp J . The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10(2):417-26. DOI: 10.1016/s1097-2765(02)00599-3. View

Voroneanu L, Ortiz A, Nistor I, Covic A . Atrial fibrillation in chronic kidney disease. Eur J Intern Med. 2016; 33:3-13. DOI: 10.1016/j.ejim.2016.04.007. View

Khouri Y, Stephens T, Ayuba G, AlAmeri H, Juratli N, McCullough P . Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. J Atr Fibrillation. 2016; 7(6):1069. PMC: 4956356. DOI: 10.4022/jafib.1069. View

Nelson S, Shroff G, Li S, Herzog C . Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc. 2012; 1(4):e002097. PMC: 3487349. DOI: 10.1161/JAHA.112.002097. View

Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1):87-92. DOI: 10.1161/01.cir.0000042700.48769.59. View

10.

Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

11.

Kumar H, Kawai T, Akira S . Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16-34. DOI: 10.3109/08830185.2010.529976. View

12.

Metivier F, Marchais S, Guerin A, Pannier B, London G . Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000; 15 Suppl 3:14-8. DOI: 10.1093/oxfordjournals.ndt.a027970. View

13.

Tsang T, Barnes M, Bailey K, Leibson C, Montgomery S, Takemoto Y . Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001; 76(5):467-75. DOI: 10.4065/76.5.467. View

14.

Vassalotti J, Centor R, Turner B, Greer R, Choi M, Sequist T . Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. Am J Med. 2015; 129(2):153-162.e7. DOI: 10.1016/j.amjmed.2015.08.025. View

15.

Lamb E, Levey A, Stevens P . The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution. Clin Chem. 2013; 59(3):462-5. DOI: 10.1373/clinchem.2012.184259. View

16.

Andrade J, Khairy P, Dobrev D, Nattel S . The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014; 114(9):1453-68. DOI: 10.1161/CIRCRESAHA.114.303211. View

17.

Piccini J, Stevens S, Chang Y, Singer D, Lokhnygina Y, Go A . Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin.... Circulation. 2012; 127(2):224-32. DOI: 10.1161/CIRCULATIONAHA.112.107128. View

18.

Umana E, Ahmed W, Alpert M . Valvular and perivalvular abnormalities in end-stage renal disease. Am J Med Sci. 2003; 325(4):237-42. DOI: 10.1097/00000441-200304000-00010. View

19.

Alikhan R, Rayment R, Keeling D, Baglin T, Benson G, Green L . The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J. 2013; 31(2):163-8. PMC: 3913117. DOI: 10.1136/emermed-2012-201976. View

20.

Mlodawska E, Tomaszuk-Kazberuk A, Lopatowska P, Musial W, Malyszko J . Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines. Pol Arch Med Wewn. 2016; 126(5):353-62. DOI: 10.20452/pamw.3431. View